CASE REPORT OF AN INCIDENTAL UNICENTRIC CASTLEMAN DISEASE

Yıl 2021, Cilt: 8 Sayı: 1, 32 - 34, 28.02.2021

Elif Cengiz , Alperen Taha Certel , Mert Yücel Ayrık , Mehmet Gürkan Arıkan , Elif Mercan Fulya Öz Puyan , İrfan Hüseyin Atakan

Öz

Aims: To emphasize the hardship of diagnosing Castleman disease and present a potential treatment method. Case Report: A sixty-three-year-old male patient was admitted to the outpatient clinic with an attack of acute cholecystitis. The patient’s abdominal computed tomography revealed an incidentally detected lipid dense solid mass (64x53x37 mm) at the level of right renal hilum with 29x13 mm solid components in the middle. The patient was admitted to the urology department and underwent surgery where the mass was totally excised due to suspicion of a malignancy (liposarcoma). Histopathological examination later on resulted with unicentric Castleman disease, hyaline vascular subtype. Conclusion: Since unicentric Castleman disease has an asymptomatic clinical course and is quite rare, it is necessary to rule out many potential possibilities before reaching a proper diagnosis. However, unicentric Castleman disease usually exhibits a good prognosis after the removal of the affected lymph node. Still, Castleman disease should be a candidate considered in the differential diagnosis of patients with incidentally discovered lymphadenopathy. On the whole, for a better understanding of underlying pathophysiology, there still lies a gap to be filled with knowledge acquired through further studies.

Anahtar Kelimeler

Castleman disease, lymphoproliferative disorder, lymphadenopathy

Kaynakça

• 1. Chan KL, Lade S, Prince HM et al. Update and new approaches in the treatment of Castleman disease. J Blood Med 2016;3(7):145-58.
• 2. Kaur H, Xiang Z, Kunthur A et al. Castleman disease. Fed Pract 2015;32(7):41-6.
• 3. Bonekamp D, Horton KM, Hruban RH et al. Castleman disease: The great mimic. RadioGraphics 2011;31:1793-807.
• 4. Munshi N, Mehra M, van de Velde H et al. Use of a claims database to charac- terize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015;56(5):1252-60.
• 5. Dispenzieri A, Armitage JO, Loe MJ et al. The clinical spectrum of Castleman's disease. Am J Hematol 2012;87(11):997-1002.
• 6. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol 2005;6(3):255-66.
• 7. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: A systemat- ic review of 404 published cases. Ann Surg 2012;255(4):677-84.
• 8. Nirhale DS, Bharadwaj RN, Athavale VS et al. Castleman's disease: A rare diagno- sis in the retroperitoneum. Indian J Surg 2013;75(1):9-11.
• 9. Nakata K, Iwahashi N, Matsukawa H et al. Laparoscopically resected Castle- man's disease in the pelvic retroperitoneum: A case report. Mol Clin Oncol 2020;12(2):169-73.
• 10. Abdessayed N, Bdioui A, Ammar H et al. Retroperitoneal unicentric Castleman's disease: A case report. Int J Surg Case Rep 2017;31:54-7.
• 11. Bracale U, Pacelli F, Milone M et al. Laparoscopic treatment of abdominal uni- centric Castleman's disease: A case report and literature review. BMC Surg 2017;17(1):38.
• 12. American Cancer Society. Treatment of Localized (Unicentric) Castleman Dis- ease (cited 2020 December 24) Available from: URL: https://www.cancer.org/ cancer/castleman-disease/treating/treating-localized.html.